Medivir AB operates in the Commercial physical research sector. Medivir AB is a Sweden-based pharmaceutical company that develops drugs against widespread diseases, with proteases as its target enzyme. It specializes in developing selective inhibitors that regulate the function of proteases in various diseases. The Company develops pharmaceuticals against major, widespread diseases like HIV, Alzheimer's disease, bone disorders and the hepatitis C segment. The Company's project portfolio comprises 10 projects, of which seven are run by partners. Medivir AB is conducting its first product launch in 2010, a pharmaceutical developed against labial herpes, which will be launched under the brand-name Xerclear in Europe and Xerese in the United States. The Company engages in a number of partnerships with established pharmaceutical companies and smaller biotechnology enterprises on clinical and preclinical projects. The group consists of the parent company Medivir AB and the subsidiaries Medivir HIV Franchise AB, Medivir Personal AB and Medivir (UK) Ltd. In our complete report available for purchase the company is compared to: Active Biotech AB, Silence Therapeutics Plc and Molmed S.P.A..